Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 26,642 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CTRL Clear all
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

NCT02652780
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 2 Interventional Results available

Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

NCT03249103
View directory record Official record
Conditions
Fibromyalgia
Interventions
NYX-2925, Placebo oral capsule
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Nov 5, 2026, 10:48 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Protein Blends on Muscle Protein Synthesis in Healthy Older Adults

NCT01847261
View directory record Official record
Conditions
Muscle Synthesis
Interventions
Soy Dairy Protein Blend, Positive Control (Dairy Whey Protein)
Dietary Supplement
Lead sponsor
DuPont Nutrition and Health
Industry
Eligibility
55 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 1 Interventional

End-stage Renal Disease (ESRD) Pilot Study

NCT03787368
View directory record Official record
Conditions
Renal Dialysis
Interventions
BAY1213790, 0.9% sodium chloride solution
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Bradenton, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Nov 5, 2026, 10:48 AM EST
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850
View directory record Official record
Conditions
Obesity and Overweight
Interventions
MET097, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Scottsdale, Arizona • Canoga Park, California • Oxnard, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

NCT03816891
View directory record Official record
Conditions
Prurigo Nodularis, Pruritis
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 5, 2026, 10:48 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of TA-65MD on Healthy Volunteers

NCT02766790
View directory record Official record
Conditions
Healthy
Interventions
TA-65MD, Placebo
Dietary Supplement · Other
Lead sponsor
Telomerase Activation Sciences, Inc
Industry
Eligibility
45 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Springfeild, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 3 Interventional

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

NCT00158990
View directory record Official record
Conditions
Major Depression, Bipolar Disorder, Unipolar Depression
Interventions
triiodothyronine, sertraline
Drug
Lead sponsor
Hadassah Medical Organization
Other
Eligibility
18 Years to 70 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2007 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 4 Interventional

Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

NCT00340613
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
glargine insulin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 19 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 3 Interventional Results available

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

NCT02234323
View directory record Official record
Conditions
Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Up to 5 Years · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
20
States / cities
Little Rock, Arkansas • Duarte, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Nov 5, 2026, 10:48 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy

NCT02451579
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Antihistamine Cetirizine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Nov 5, 2026, 10:48 AM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO17)

NCT05745662
View directory record Official record
Conditions
Hypoxia
Interventions
Pulse Oximeter
Device
Lead sponsor
Nihon Kohden
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Nov 5, 2026, 10:48 AM EST
Recruiting Phase 3 Interventional

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

NCT07335588
View directory record Official record
Conditions
Lichen Sclerosus
Interventions
Delgocitinib, Cream Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 5, 2026, 10:48 AM EST
Recruiting Phase 2 Interventional Accepts healthy volunteers

Dose Regimen Study of SLI-F06 in Healthy Volunteers

NCT05501327
View directory record Official record
Conditions
Scar, Wound Healing
Interventions
SLI-F06
Drug
Lead sponsor
Scarless Laboratories, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Encinitas, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

NCT01725126
View directory record Official record
Conditions
Obesity
Interventions
GSK2890457, Metformin, Placebo, Liraglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Nov 5, 2026, 10:48 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial of Mental Health Peer-Led Education

NCT01297985
View directory record Official record
Conditions
Mental Disorders
Interventions
BRIDGES Peer-Led Education
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 2 Interventional Results available

Randomized Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid

NCT01400815
View directory record Official record
Conditions
Smoking Cessation
Interventions
X-22 Smoking Cessation Product, Active Control Cigarettes
Drug
Lead sponsor
22nd Century Limited, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Sacramento, California • Metairie, Louisiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Nov 5, 2026, 10:48 AM EST
Not listed Phase 3 Interventional

CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1

NCT02504008
View directory record Official record
Conditions
Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy
Interventions
AXS-02 (oral zoledronate), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
29
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Nov 5, 2026, 10:48 AM EST
Completed Not applicable Interventional Results available

A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis

NCT00727740
View directory record Official record
Conditions
Pancreatitis
Interventions
Indomethacin, Placebo suspension
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 2 Interventional Results available

Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

NCT01381718
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Fatigue, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions
modafinil, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 19 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
60
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 3 Interventional Results available

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

NCT04626297
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
85
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • North Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 1 Interventional

Deoxycholic Acid Injection for the Treatment of Superficial Lipomas

NCT00422188
View directory record Official record
Conditions
Lipoma
Interventions
Deoxycholic Acid Injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03945188
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Dothan, Alabama • Sun City, Arizona • Lancaster, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Nov 5, 2026, 10:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of SPY002-091 in Healthy Volunteers

NCT06672718
View directory record Official record
Conditions
Healthy
Interventions
SPY002-091, Placebo
Drug · Other
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 5, 2026, 10:48 AM EST